Table 1

Baseline characteristics associated with prior TB diagnosis

Univariate

Multivariate


Characteristics

No. patients

No.(%) with prior TB

OR

p-value

OR (95%CI)

p-value


Total

3279

717 (22%)

Sex

Male

2307

582 (25%)

Female

972

135 (14%)

0.48

<0.001

0.38 (0.30, 0.47)

<0.001

Age (years)

< = 30

783

141 (18%)

31~40

1481

366 (25%)

1.49

<0.001

1.39 (1.10, 1.76)

0.006

41+

1015

210 (21%)

1.19

0.155

1.16 (0.89, 1.51)

0.261

Reported mode of infection

Heterosexual contact

2288

584 (26%)

Homosexual contact

614

66 (11%)

0.35

<0.001

0.47 (0.34, 0.63)

<0.001

Injecting drug use

132

34 (26%)

1.01

0.952

0.73 (0.47, 1.12)

0.154

Blood product

120

11 (9%)

0.29

<0.001

0.29 (0.15, 0.56)

<0.001

Other/unknown

125

22 (18%)

0.62

0.049

0.60 (0.37, 0.98)

0.042

CD4 count at entry to TAHOD (cells/μL)

< = 50

241

84 (35%)

51–100

209

78 (37%)

1.11

0.587

1.06 (0.74, 1.59)

0.780

101–200

524

142 (27%)

0.69

0.029

0.71 (0.50, 1.00)

0.054

201–300

578

121 (21%)

0.49

<0.001

0.58 (0.41, 0.83)

0.003

301+

1487

217 (15%)

0.32

<0.001

0.42 (0.30, 0.58)

<0.001

Not tested

240

75 (31%)

0.85

0.401

0.91 (0.61, 1.38)

0.665

HIV viral load at entry to TAHOD (copies/mL)

< = 399

1133

188 (17%)

400~10,000

188

24 (13%)

0.74

0.187

0.93 (0.58, 1.50)

0.774

10,001+

405

54 (13%)

0.77

0.123

0.92 (0.64, 1.32)

0.652

No. not tested

1553

451 (29%)

2.06

<0.001

1.36 (1.05, 1.76)

0.018

Antiretroviral treatment at entry to TAHOD

No treatment

830

117 (14%)

On treatment

2449

600 (25%)

1.98

<0.001

1.99 (1.56, 2.56)

<0.001

Country of TB burden

High

1990

547 (27%)

Low/intermediate

1289

170 (13%)

0.40

<0.001

0.55 (0.42, 0.70)

<0.001


OR: odds ratio. CI: confidence intervals.

Zhou et al. BMC Infectious Diseases 2009 9:46   doi:10.1186/1471-2334-9-46

Open Data